(232 days)
None
No
The summary describes a physical hemostatic pad and its performance characteristics, with no mention of AI or ML technologies.
Yes
The device is intended for the local management of bleeding wounds and for the promotion of rapid control of bleeding, which directly addresses a medical condition (bleeding) and provides a therapeutic effect (hemostasis).
No
Explanation: The InnoSEAL Hemostatic Pad is designed for the local management of bleeding wounds and promotion of rapid bleeding control. Its function is to stop bleeding, not to diagnose a condition or disease.
No
The device description clearly states it is a physical pad made of chitosan and catechol conjugated chitosan, applied topically. It is a tangible, physical medical device, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the local management of bleeding wounds and promotion of rapid control of bleeding. This is a therapeutic or wound management function, not a diagnostic one.
- Device Description: The device is a pad applied topically to a wound. It does not involve testing samples from the human body in vitro (outside the body) to provide diagnostic information.
- Performance Studies: The performance studies focus on biocompatibility, liquid absorption, physical/chemical properties, packaging, sterility, shelf life, microbiological safety, and in-vivo hemostasis in an animal model. These are all related to the device's function in managing bleeding, not diagnosing a condition.
- Lack of Diagnostic Elements: There is no mention of analyzing biological samples, detecting biomarkers, or providing information about a patient's health status or disease.
IVD devices are specifically designed to examine specimens derived from the human body (like blood, urine, tissue) to provide information for diagnostic, monitoring, or screening purposes. This device does not fit that description.
N/A
Intended Use / Indications for Use
InnoSEAL Hemostatic Pad is intended for the local management of bleeding wounds and for the promotion of rapid control of bleeding. InnoSEAL Hemostatic Pad is intended for use under the care of a healthcare professional.
The dressing is indicated for following wounds; lacerations, abrasions and the skin surface puncture sites for vascular procedures, percutaneous catheters/tubes.
Product codes
QSY, FRO
Device Description
InnoSEAL Hemostatic Pad is a hydrophilic, lyophilized sponge pad for local management of bleeding wound made of proprietary formulation of chitosan and catechol conjugated chitosan which are biocompatible. InnoSEAL Hemostatic Pad is applied topically as an adjunct to manual compression. InnoSEAL Hemostatic Pad is a single use device individually packaged by PET mold and Aluminum lid and sterilized with gamma irradiation.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
under the care of a healthcare professional
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Biocompatibility tests: Acute systemic toxicity, Cytotoxicity, Skin Sensitization, Intracutaneous Reactivity, Endotoxin. Results met all relevant requirements.
Comparative liquid absorption test: Both hemostatic pads (subject and predicate) presented fast liquid absorption rates and liquid absorption capability of InnoSEAL Hemostatic Pad was equivalent to predicate device.
Identification tests: Comparative FT-IR analysis of chitosan and InnoSEAL Hemostatic Pad, Gelation test.
Physical/Chemical tests: Appearance, Residue on ignition, Degree of oxidation, Loss on drying, Heavy metal, pH, Residual solvent, Deacetylation degree.
Packaging tests: Qualification test and evaluation of blister packaging machine, Burst test, Tensile / Tearing / Heat-sealing strength test, Dye penetration test.
Sterility and Shelf life tests: Sterilization validation test, Accelerated stability test, Real-time stability test.
Microbiological safety tests: Virus clearance tests were conducted to support adequacy of virus inactivation during the manufacture of InnoSEAL Hemostatic Pad. The studies demonstrated that efficient virus inactivation manufacturing steps are included with complete inactivation result of model viruses.
Animal tests: In-vivo hemostasis test using swine femoral artery hemorrhage model (study 15-KE-136) was performed. InnoSEAL Hemostatic Pad and predicate device showed superior hemostatic efficacy compared to manual compression with regular gauze. Gross necropsy and histopathological evaluations were similar and comparable between the groups. In overall, InnoSEAL Hemostatic Pad was effective and shortened the time to hemostasis at injured femoral artery access sites. InnoSEAL Hemostatic Pad was safe and effective for its intended use.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
No reference devices were used in this submission.
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
N/A
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, with the word "ADMINISTRATION" underneath.
April 21, 2023
InnoTherapy Inc. % Robert Schiff, Ph.D., RAC, CQA, FRAPS Schiff & Company, Inc. 1120 Bloomfield Ave. West Caldwell, New Jersey 07282
Re: K161013 Trade/Device Name: InnoSEAL Hemostatic Pad Regulatory Class: Unclassified Product Code: QSY
Dear Dr. Robert Schiff:
The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated November 29, 2016. Specifically, FDA is updating this SE Letter because FDA has better categorized your device technology under product code QSY.
Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact Julie Morabito, OHT4: Office of Surgical and Infection Control Devices, 240-402-3839, Julie.Morabito@fda.hhs.gov.
Image /page/0/Picture/7 description: The image shows a letter closing with the name Julie A. Morabito. The next line shows Julie Morabito, Ph.D., followed by Assistant Director. The last line shows DHT4B: Division of Infection Control.
and Plastic Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
1
Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
November 29, 2016
InnoTherapy, Inc. Robert Schiff, Ph.D., RAC, CQA, FRAPS Schiff & Company, Inc. 1120 Bloomfield Ave. West Caldwell, NJ 07006
Re: K161013
Trade/Device Name: InnoSEAL Hemostatic Pad Regulatory Class: Class: Unclassified Product Code: FRO Dated: October 31, 2016 Received: November 1, 2016
Dear Dr. Schiff:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
2
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
David Krause -S
for
Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K161013
Device Name
InnoSEAL Hemostatic Pad
Indications for Use (Describe)
InnoSEAL Hemostatic Pad is intended for the local management of bleeding wounds and for the promotion of rapid control of bleeding. InnoSEAL Hemostatic Pad is intended for use under the care of a healthcare professional.
The dressing is indicated for following wounds; lacerations and the skin surface puncture sites for vascular procedures, percutaneous catheters/tubes.
Type of Use (Select one or both, as applicable)
2 Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
510(k) Summary
(1) SUBMITTER:
InnoTherapy Inc. Ace Hightechcity2, 25, Seonyu-ro 13-gil, Yeongdeungpo-gu, Seoul, 07282 Republic of Korea Telephone : +82 (2) 6959 1338 Contact person : Moon Sue Lee, CEO Date prepared : October 31, 2016
(2) DEVICE NAME: InnoSEAL Hemostatic Pad Trade Name: InnoSEAL Hemostatic Pad Common Name: Topical Hemostasis Pad Classification Name: Topical Wound Dressing Pad Device Class: Unclassified Product Code: FRO
- (3) PREDICATE DEVICE: Substantial equivalence is based on following legally marketed devices.
The predicates have not been subject to a design-related recall. No reference devices were used in this submission.
- (4) DESCRIPTION OF THE DEVICE: InnoSEAL Hemostatic Pad is a hydrophilic, lyophilized sponge pad for local management of bleeding wound made of proprietary formulation of chitosan and catechol conjugated chitosan which are biocompatible. InnoSEAL Hemostatic Pad is applied topically as an adjunct to manual compression. InnoSEAL Hemostatic Pad is a single use device individually packaged by PET mold and Aluminum lid and sterilized with gamma irradiation.
- (5) INTENDED USE: InnoSEAL Hemostatic Pad is intended for the local management of bleeding wounds and for the promotion of rapid control of bleeding. InnoSEAL Hemostatic Pad is intended for use under the care of a healthcare professional.
The dressing is indicated for following wounds; lacerations, abrasions and the skin surface puncture sites for vascular procedures, percutaneous catheters/tubes.
InnoSEAL Hemostatic Pad has essentially the same intended use as the predicate device.
- (6) TECHNOLOGICAL CHARACTERISTICS: InnoSEAL Hemostatic Pad is made of proprietary formulation of chitosan and catechol conjugated chitosan and is comprised of massively porous sponge. InnoSEAL Hemostatic Pad achieves the principal intended action of hemostasis by providing a physical barrier and effective
5
510(K) Premarket Notification for InnoSEAL Hemostatic Pad InnoTherapy Inc.
blood absorption to stop bleeding. Chitosan is a naturally occurring polysaccharide derived from shellfish. The natural biological property of chitosan caries cation (positively charged ion) that helps to stop external hemorthage. In addition, catechol conjugated chitosan aids hemostasis by coating surface of bleeding area and forming a physical barrier enabling prompt control of bleeding and protection against foreign element contamination.
6
- (7) COMPARISON WITH PREDICATE DEVICES: Following table is a comparison of our new InnoSEAL Hemostatic Pad and predicate devices.
| | InnoSEAL Hemostatic
Pad | Predicate 1
Clo-Sur Plus P.A.D.
(K032986) | Predicate 2
Hemo-Pad (K102944) |
|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Product Code | FRO | FRO | FRO |
| Prescription /
OTC | Prescription | Prescription | Prescription |
| Physical
Composition | a hydrophilic, lyophilized
sponge pad made of
proprietary formulation of
chitosan and catechol
conjugated chitosan | a soft, non-woven pad
made of a proprietary
formulation of
poly-D-glucosamine and
poly-N-acetylglucosamine
derived from chitosan. | a soft, non-woven topical
pad made of
poly-D-glucosamine and
poly-N-acetylglucosamine
derived from chitosan. |
| Intended Use | Local management of
bleeding wounds and for
the promotion of rapid
control of bleeding.
The dressing is indicated
for following wounds;
Lacerations, Abrasions and
the skin surface puncture
sites for vascular
procedures, percutaneous
catheters/tubes. | Local management of
bleeding wounds and to
provide a barrier to
bacterial penetration of the
dressing in all patients and
for the promotion of rapid
control (hemostasis) of
bleeding in patients
following hemodialysis and
for those on anticoagulation
therapy.
The dressing is indicated
for the following wounds:
lacerations, abrasions, nose
bleeds, and the skin surface
puncture sites for vascular
procedures, percutaneous
catheters or tubes. | topical wound management
and for the external topical
temporary control of
moderate to severe
bleeding.
The dressing is indicated
for the following wounds:
abrasions, lacerations, skin
surface puncture sites for
vascular procedures
(arteries
and veins) |
| Single Use Only | Yes | Yes | Yes |
| Biocompatibility | Biocompatible | Biocompatible | Biocompatible |
| Sterilization
Method and
Level | sterilized by gamma-ray
radiation to a 106 SAL. | sterilized by E-beam
radiation to a 106 SAL. | sterilized by gamma-ray
radiation to a 106 SAL. |
Use of chitosan as a hemostatic agent for the control of bleeding is the technical principle for both the subject and predicate devices. (K032986, K102944) It is based on the natural biological property of chitosan that carries cation (positively charged ion) that helps to stop external hemorrhage.
7
At a high level, the subject and predicate devices are based on the following same technological elements:
- . Chitosan - used as a hemostatic agent
- Device applied topically as an adjunct to manual compression
- Topical pad to absorb blood and wound exudates ●
The following technological differences exist between the subject and predicate devices:
-
Use of catechol conjugated chitosan
InnoSEAL Hemostatic Pad has small quantity of catechol conjugated chitosan while predicate devices do not have. This slight difference is insignificant and does not affect the intended use and performance of the device. InnoSEAL Hemostatic Pad and its predicate devices are made from similar materials, utilize the same hemostatic mechanism, and have similar intended use. -
PERFORMANCE DATA: The following performance data has been provided in support of the (8) substantial equivalence determination.
Biocompatibility tests
Biocompatibility tests were conducted following procedures outlined in the respective consensus standards, and results for InnoSEAL Hemostatic Pad met all relevant requirements in the test standards. The battery of testing included the following tests:
- Acute systemic toxicity ●
- Cytotoxicity
- Skin Sensitization ●
- Intracutaneous Reactivity
- Endotoxin
The intended use of the InnoSEAL Hemostatic Pad puts it within the biocompatibility category of limited contact duration, and breached/compromised surface device.
Comparative liquid absorption test
Liquid absorption test was conducted on the InnoSEAL Hemostatic Pad and the predicate device. Both hemostatic pads presented fast liquid absorption rates and liquid absorption capability of InnoSEAL Hemostatic Pad was equivalent to predicate device.
Identification tests
- Comparative FT-IR analysis of chitosan and InnoSEAL Hemostatic Pad ●
- Gelation test
8
Physical/Chemical tests
- Appearance
- . Residue on ignition
- Degree of oxidation ●
- Loss on drying ●
- Heavy metal ●
- pH
- Residual solvent ●
- Deacetylation degree ●
Packaging tests
- Qualification test and evaluation of blister packaging machine ●
- Burst test ●
- Tensile / Tearing / Heat-sealing strength test
- Dye penetration test
Sterility and Shelf life tests
- Sterilization validation test
- Accelerated stability test ●
- Real-time stability test ●
Microbiological safety tests
Virus clearance tests were conducted to support adequacy of virus inactivation during the manufacture of InnoSEAL Hemostatic Pad. The studies demonstrated that efficient virus inactivation manufacturing steps are included with complete inactivation result of model viruses.
Animal tests
In-vivo hemostasis test using swine femoral artery hemorrhage model was performed to demonstrate the effectiveness and safety of InnoSEAL Hemostatic Pad. In study 15-KE-136. InnoSEAL Hemostatic Pad and predicate device showed superior hemostatic efficacy compared to manual compression with regular gauze. Gross necropsy and histopathological evaluations were similar and comparable between the groups. In overall, InnoSEAL Hemostatic Pad was effective and shortened the time to hemostasis at injured femoral artery access sites. InnoSEAL Hemostatic Pad was safe and effective for its intended use.
9
The collective results of the bench and animal testing demonstrate that the materials chosen, the manufacturing process, and the design of the InnoSEAL Hemostatic Pad meet the established specifications necessary for the consistent performance during its intended use. In addition, the tests demonstrate that the InnoSEAL Hemostatic Pad does not raise new questions of effectiveness or safety for its intended use when compared to the predicate devices.
- (9) CONCLUSION: Based on the comparison of intended use, design, materials, and performance, InnoSEAL Hemostatic Pad is substantially equivalent to legally marketed predicate devices and is safe and effective for its intended use.